CY1115269T1 - Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους - Google Patents

Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους

Info

Publication number
CY1115269T1
CY1115269T1 CY20141100469T CY141100469T CY1115269T1 CY 1115269 T1 CY1115269 T1 CY 1115269T1 CY 20141100469 T CY20141100469 T CY 20141100469T CY 141100469 T CY141100469 T CY 141100469T CY 1115269 T1 CY1115269 T1 CY 1115269T1
Authority
CY
Cyprus
Prior art keywords
naloxone
medicine
preparation
naltrexone
therapeutic treatment
Prior art date
Application number
CY20141100469T
Other languages
English (en)
Inventor
Ibrahim Mustafa Iskender Pisak
Mehmet Levent Selamoglu
Nevhiz Pak
Semra Bingol
Original Assignee
Imuneks Farma Ilaç Sanayi Ve Ticaret A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. filed Critical Imuneks Farma Ilaç Sanayi Ve Ticaret A.S.
Publication of CY1115269T1 publication Critical patent/CY1115269T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Οι εκφυλιστικές ασθένειες του αμφιβληστροειδούς επηρεάζουν την εύθραυστη στιβάδα του αμφιβληστροειδικού ιστού που επενδύει το εσωτερικό πίσω μέρος του οφθαλμού, οδηγώντας σε βαθμιαία απώλεια όρασης. Η χρήση ανταγωνιστών οπιοειδών για την παρασκευή ενός φαρμάκου για την εκλεκτική δέσμευση των τοποθεσιών οπιοειδών υποδοχέων του σώματος είναι μια μέθοδος αντιμετώπισης αυτής της ανθρώπινης πάθησης με ημερήσια χορήγηση στον ασθενή, από περίπου 0,5 έως περίπου 10 mg φαρμάκων, όπως ναλτρεξόνης, ναλοξόνης ή ναλμεφαίνης. Δρουν πρώτα μέσω κανονικοποίησης των αποδιατάξεων στο ανθρώπινο σύστημα συμπληρώματος που μπορεί να λάβουν χώρα στην αιτιολογία της ασθένειας. Στοχεύεται πρωταρχικά μια θεραπευτική προσέγγιση για τον εκφυλισμό της ωχράς κηλίδας και την μελαγχρωστική αμφιβληστροειδίτιδα. Από του στόματος, παρεντερικές χρήσεις, καθώς και τοπικές εφαρμογές, μπορεί όλα να εξετάζονται. Μπορεί να χορηγούνται σε μια ή σε διηρημένες δόσεις για την καλύτερη δραστικότητα δέσμευσης υποδοχέα, κατά προτίμηση στις βραδινές ώρες. Χαμηλής Δόσης Ναλτρεξόνη κατάλληλη για από του στόματος χορήγηση είναι η περισσότερο προτιμώμενη αγωγή περίπου στα 4,5 mg/ημέρα.
CY20141100469T 2008-09-16 2014-06-26 Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους CY1115269T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08807092.5A EP2379066B1 (en) 2008-09-16 2008-09-16 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
PCT/IB2008/002412 WO2010032073A1 (en) 2008-09-16 2008-09-16 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases

Publications (1)

Publication Number Publication Date
CY1115269T1 true CY1115269T1 (el) 2017-01-04

Family

ID=41138810

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100469T CY1115269T1 (el) 2008-09-16 2014-06-26 Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους

Country Status (10)

Country Link
US (1) US20110165232A1 (el)
EP (1) EP2379066B1 (el)
CY (1) CY1115269T1 (el)
DK (1) DK2379066T3 (el)
ES (1) ES2475199T3 (el)
HR (1) HRP20140596T1 (el)
PL (1) PL2379066T3 (el)
PT (1) PT2379066E (el)
SI (1) SI2379066T1 (el)
WO (1) WO2010032073A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201203732T1 (tr) * 2009-10-01 2012-09-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
CN102946870A (zh) 2010-05-10 2013-02-27 欧洲凯尔特公司 包含氢吗啡酮和纳洛酮的药物组合物
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US20140213605A1 (en) * 2013-01-27 2014-07-31 Remedeye Inc. Methods for treating eye disorders using opioid receptor antagonists
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5356900A (en) * 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US20030072724A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition to treat hyperpigmentation of the skin
US6538028B1 (en) 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US20030235542A1 (en) * 2002-06-21 2003-12-25 Maibach Howard I. Topical administration of pharmacologically active bases for skin lightening
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2011009020A2 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TR201203732T1 (tr) * 2009-10-01 2012-09-21 Ak Ki̇mya İthalat-İhracat Ve Sanayi̇i̇ A.Ş. Opioid antagonistlerin topikal bileşimleri ve deri hastalıklarının bu bileşimler ile tedavisi için yöntemler.
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.

Also Published As

Publication number Publication date
EP2379066B1 (en) 2014-03-26
WO2010032073A1 (en) 2010-03-25
SI2379066T1 (sl) 2014-08-29
PT2379066E (pt) 2014-07-04
PL2379066T3 (pl) 2014-09-30
US20110165232A1 (en) 2011-07-07
DK2379066T3 (da) 2014-06-30
EP2379066A1 (en) 2011-10-26
ES2475199T3 (es) 2014-07-10
HRP20140596T1 (hr) 2014-08-01

Similar Documents

Publication Publication Date Title
CY1115269T1 (el) Χρηση ανταγωνιστων οπιοειδων για την παρασκευη ενος φαρμακου στη θεραπευτικη αγωγη εκφυλιστικων ασθενειων του αμφιβληστροειδους
CY1117916T1 (el) Θεραπεια διαταραχων που σχετιζονται me bdnf χρησιμοποιωντας laquinimod
ES2241651T3 (es) Utilizacion de la nicotina o de sus derivados y de la l-dopa en un medicamento destinado al tratamiento de enfermedades neurologicas, especialmente la enfermedad de parkinson.
CY1113253T1 (el) Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
AU2016208779B2 (en) Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
JP2019517542A5 (el)
TW201249425A (en) Cannabinoids for use in the treatment of neuropathic pain
KR101900520B1 (ko) 복합 조성물
ES2704987T3 (es) Composiciones farmacéuticas para terapia de combinación
JP2016521755A5 (el)
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
US20180015098A1 (en) Apilimod compositions and methods for using same
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
BRPI0804623A2 (pt) uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos
BR9913746F1 (pt) derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral, e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento
Im et al. Management of sleep disorders in stroke
WO2010129340A3 (en) Novel photosensitizer formulations for oral administration
WO2008120966A1 (es) Composición farmacéutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgésico opiáceo para el manejo del dolor.
Serafini et al. The use of rotigotine in the treatment of restless legs syndrome
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы
RU2572504C1 (ru) Способ лечения лучевой сиалоаденопатии
Steineck Fenretinide/isotretinoin
Alipour et al. Comparison of Analgesic Effects of B Vitamins and Diclofenac plus B Vitamins During General Anesthesia and PACU
Dolhun et al. Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys